Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (August 16th Preview)
-
Multiple myeloma regulatory approval
Bristol Myers Squibb won FDA accelerated approval for Zenbexus (iberdomide) in combination with daratumumab, hyaluronidase-fihj, and dexamethasone for adults with advanced multiple myeloma. The approval marks the debut of CELMoDs, a protein-degrader class aimed at improving depth of response in the relapsed setting. In a key trial result underpinning the decision, the Zenbexus regimen produced higher rates of minimal residual disease negativity than a Velcade-containing comparator. BMS said it will provide further results on broader clinical outcomes as follow-on data mature. Separately, analysts highlighted that the approval could reshape second-line regimen choices by increasing the addressable population for CELMoDs—setting up a competitive shift versus daratumumab-based strategies already in use.
-
Duchenne muscular dystrophy regulatory path
Capricor moved to re-position deramiocel after prior setbacks with the FDA, announcing plans to amend its BLA to target improved limb function in Duchenne muscular dystrophy. The company said it expects to file additional data and analysis following the FDA’s willingness to review an updated submission. The strategy shift followed controversy around the HOPE-3 Phase 3 program endpoints, where an FDA advisory committee previously focused on secondary findings. Capricor’s updated goal is narrower than its earlier indication, seeking to align the regulatory narrative with functional benefit. The company’s latest disclosures also prompted renewed investor attention after deramiocel’s earlier complete response letter, as shareholders bet on an FDA-focused pathway correction.
-
Cell therapy resurgence via open-label FDA-cleared data
Capricor’s deramiocel gained a fresh investor tailwind after the company reported additional open-label extension results tied to Duchenne muscular dystrophy cardiomyopathy. The update followed an FDA green light to review the new evidence, renewing debate over whether the therapy can meet regulatory requirements. The company’s disclosure highlighted how responses may be maintained or re-established in certain patient groups, including outcomes observed after additional treatment phases. While the FDA’s position on endpoints remains central, the new data package is intended to strengthen the overall benefit argument. Capricor’s share reaction underscored how quickly regulatory interaction and endpoint framing can move sentiment in rare-disease cell therapy.
-
Multiple myeloma: manufacturing and AI discovery collaboration
Bristol Myers Squibb selected Houston for a new $2.3 billion multi-modal manufacturing campus to produce drug product and finished goods from late development through commercial launch. The plan expands BMS’s capacity footprint as it scales platform assets and supports multiple programs across modalities. At the same time, Recursion and Roche—including Genentech—announced plans to co-develop a neuroscience discovery program based on a validated target identified through an AI map. The partnership links discovery outputs from machine-learning target finding to program-level development. The package of updates highlights BMS’s dual focus: ramping manufacturing depth while pairing AI-discovery collaborations to build future pipeline entries, particularly in disease areas where target validation is a gating step.
-
Gene therapy deal: Sangamo Fabry asset sold via auction
PTC Therapeutics won a competitive auction to acquire Sangamo’s Fabry gene therapy program ST-920 (isaralgagene civaparvovec). Under the terms reported, Sangamo will receive $111 million upfront and another $100 million tied to regulatory milestones. The deal emerged from Sangamo’s bankruptcy asset sale process, with PTC outbidding Astellas and TerSera Therapeutics. ST-920 is designed to deliver a functional copy of alpha-galactosidase A via one-time AAV gene therapy to address underlying enzyme deficiency in Fabry disease. During Sangamo’s Phase I/II STAAR study, participants on enzyme replacement therapy stopped treatment following dosing, supporting the concept of a durable shift in disease biology. PTC positioned the acquisition as a route to accelerate revenue growth without a full internal build.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.